Table 7 Association between ctDNA before and after ICI and clinical outcome
Biomarker | NSCLC stage (n) | Treatment | Direction | Association with clinical outcome | Ref | |||
|---|---|---|---|---|---|---|---|---|
Response | PFS | OS | ||||||
Baseline | ctDNA | III-IV (n = 10 studies) | ICI based | ↓ | ns | ns | ns | [105] |
IV nonsquamous (n = 446) | αPD-L1/bev/chemo, αPD-L1/chemo, bev/chemo | ↓ | ↑ (p = 0.002) | ↑ (p < 0.001) | [104] | |||
IV squamous (n = 221) | αPD-L1/chemo, chemo | ↓ | ↑ | ↑ | [103] | |||
Post treatment | ctDNA | III-IV (n = 10 studies) | ICI based | ↓ | ↑ (p < 0.001) | ↑ (p < 0.001) | ↑ (p < 0.001) | [105] |
IV nonsquamous (n = 446) | αPD-L1/bev/chemo, αPD-L1/chemo, bev/chemo | ↓ (model) | ↑ (p < 0.001) | [104] | ||||
IV squamous (n = 221) | αPD-L1/chemo, chemo | ↓ | ↑ | ↑ (p < 0.001) | ↑ (p < 0.001) | [103] | ||
III-IV squamous (n = 134) | αPD-1/chemo | ↓ | ↑ (p = 0.004) | ↑ (p < 0.001) | ↑ (p < 0.001) | [102] | ||